Connect your AI

Precigen PGEN Remainder of Fiscal Year 2024

Remainder of Fiscal Year 2024 at other companies

Agios PharmaceuticalsAGIO

——

BridgeBio PharmaBBIO

——

AmgenAMGN

——

Other financials

Income statement

Revenue$23.3M+1,634%

Operating income-$6.0M+73.5%

Net income-$7.9M+85.4%

EPS (diluted)-$0.02+88.9%

Balance sheet

Cash & equivalents$7.5M+23.5%

Total debt$98.3M+1,714%

Total equity$20.2M+244%

Total assets$138.6M+7.6%

Cash flow

Operating cash flow-$43.8M-168%

CapEx$258.0K-58.5%

Free cash flow-$44.1M-160%

Valuation

Market cap$1.91B+213%

Enterprise value$2B+234%

P/S72×—

Profitability

Gross margin83.6%—

Operating margin-2,890.9%—

Net margin-3,656%—

FCF margin-1,756.5%—

Returns & leverage

Return on equity-843.6%-1,103pp

Debt / equity4.9×—

Current ratio4.8×+1.3×

Where this comes from

Reported directly by Precigen in its filing.

Tagged under the XBRL concept us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear.

The official record: Precigen’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Precigen's remainder of fiscal year 2024.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Precigen's remainder of fiscal year 2024?: Precigen (PGEN) reported remainder of fiscal year 2024 of $1.15M in Q1 2026.
How has Precigen's remainder of fiscal year 2024 changed year-over-year?: Precigen's remainder of fiscal year 2024 increased by 2.2% year-over-year, from $1.13M to $1.15M.